Erythrocyte Patents (Class 435/7.25)
-
Patent number: 8889369Abstract: A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains DNA (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample.Type: GrantFiled: November 8, 2013Date of Patent: November 18, 2014Assignee: Litron Laboratories, Ltd.Inventor: Stephen D. Dertinger
-
Publication number: 20140315748Abstract: The invention provides a method for isolating or enriching a rare cell from a biological fluid of a mammal employing an antibody that binds a cell-surface antigen of the rare cell. The immobilized antibody is incubated with a sample of biological fluid that includes the rare cells and a plurality of other cells so as to form an antibody-rare cell complex. The complex can be detected or isolated and subsequently analyzed by any of a variety of physical, chemical and genetic techniques.Type: ApplicationFiled: November 13, 2012Publication date: October 23, 2014Inventors: Javad Khosravi, Leonard H. Kellner, Hassan Bennani
-
Patent number: 8841082Abstract: The invention relates to a method for determining one or more cellularly bound analytes in a liquid sample, said method being carried out using a device comprising: at least one feeding zone (5) for applying the liquid sample; a porous membrane (2) that is suitable for letting cellular components penetrate therethrough and includes at least one indicator zone on the membrane, said indicator zone being able to interact with the cellularly bound analyte and containing at least one binding element against the cellularly bound analyte; and at least one absorption area (3) on the membrane, which absorbs the liquid after the liquid has passed the indicator zones. The at least one indicator zone lies between the feeding zone (5) and the absorption area (3).Type: GrantFiled: December 14, 2007Date of Patent: September 23, 2014Assignee: Medion Diagnostics AGInventors: Peter Schwind, Iwan Aebischer
-
Patent number: 8828737Abstract: Methods for using focused light scattering techniques for the optical sensing of biological particles suspended in a liquid medium are disclosed. The optical sensing enables one to characterize particles size and/or distribution in a given sample. This, in turn, allows one to identify the biological particles, determine their relative particle density, detect particle shedding, and identify particle aggregation. The methods are also useful in screening and optimizing drug candidates, evaluating the efficacy and dosage levels of such drugs, and in personalized medicine applications.Type: GrantFiled: July 14, 2009Date of Patent: September 9, 2014Assignee: Invitrox, Inc.Inventor: Don Gabriel
-
Patent number: 8802385Abstract: The present invention relates to a new suspension medium or diluent solution for red blood cells for use in haematological methods. The suspension medium or diluent solution for red blood cells may comprise a combination of two or more amino acids of any group, and preserves the red blood cells in the sample for at least 8 weeks.Type: GrantFiled: June 22, 2007Date of Patent: August 12, 2014Assignee: Grifols, S.A.Inventors: Daniel Martorell Pena, Ma del Carmen Traves Polo, Jordi Farre Leon, Josefina Castells Parera
-
Publication number: 20140206019Abstract: The present invention discloses a method of assaying Fc-function in an immunoglobulin containing sample by contacting the sample, in the presence of a complement, with red blood cells modified to incorporate a F-S-L peptide-lipid construct. The F-S-L peptide construct comprises a functional group (F) that is a target antigen for a complement activating immunoglobulin, a spacer group (S) covalently linking F to L and a lipid group (L). The present invention further discloses a specific construct, DOPE-Ad-CMG(2)-hCMV2 where the F group is an antigen of cytomegalovirus, that is used in assaying the Fc function of an intravenous immunoglobulin (IVIG) product.Type: ApplicationFiled: March 5, 2012Publication date: July 24, 2014Applicant: Kode Biotech LimitedInventors: Stephen Micheal Henry, Venkata Sarvani Komarraju
-
Publication number: 20140154704Abstract: The present invention concerns a monoclonal antibody and corresponding hybridoma cells and antigens suitable for isolating fetal cells from maternal blood. The inventive monoclonal antibody reacts with a surface antigen present on fetal red blood cells including their nucleated precursor cells, but not with surface antigens on adult erythroid cell.Type: ApplicationFiled: September 16, 2013Publication date: June 5, 2014Applicant: Adnagen AGInventors: Christiane Hollmann, Silke Zimmermann, Stefan Stachelhaus, Winfried Albert
-
Publication number: 20140141997Abstract: In one aspect, the invention is directed to methods of separating foetal nucleated red blood cells (FNRBCs) from a sample comprising contacting the sample with an agent that specifically recognizes CD147, thereby producing a mixture; maintaining the mixture under conditions in which a complex forms between the agent and the CD147 in the sample; and separating the complex from the mixture; thereby separating the FNRBCs from the sample. In other embodiments, the invention is directed to methods of detecting FNRBCs in a sample comprising contacting the sample with an antibody or antigen binding fragment thereof that specifically binds CD147, thereby producing a combination; maintaining the combination under conditions in which an immune complex forms between the antibody and FNRBCs present in the sample; and detecting whether the immune complex forms in the combination; wherein if the immune complex is detected then FNRBCs are present in the sample.Type: ApplicationFiled: June 28, 2012Publication date: May 22, 2014Applicant: NATIONAL UNIVERSITY OF SINGAPOREInventors: Aniza Puteri Mahyuddin, Sukumar Ponnusamy, Priya Kadam, Mahesh Choolani
-
Publication number: 20140134648Abstract: Methods of determining health status based on analysis of single cells in a sample or set of samples from an individual are described.Type: ApplicationFiled: October 3, 2013Publication date: May 15, 2014Applicant: NODALITY, INC.Inventors: Wendy J. Fantl, Helen L. Francis-Lang, Aileen C. Cohen, Garry P. Nolan
-
Patent number: 8691515Abstract: Disclosed herein are methods of detecting blood disorders, such as diabetes. In particular examples the method includes contacting a blood sample with an amine reagent, blocking an excess of the amine reagent with a blocking reagent, digesting the modified blood sample with trypsin to produce a digested blood sample containing a plurality of glycated N-terminal peptides and non-glycated N-terminal peptides, then analyzing the digested blood sample with MALDI MS. Also provided are reagents for use in such methods.Type: GrantFiled: July 7, 2010Date of Patent: April 8, 2014Assignee: UVic Industry Partnerships Inc.Inventors: Evgeniy V. Petrotchenko, Christoph Borchers
-
Publication number: 20140093540Abstract: Immunogenic compositions and vaccines against Plasmodial infection comprising an Rh polypeptide or a fragment or variant thereof are disclosed. Also disclosed are Rh5 polypeptides or fragments or variants thereof capable of binding CD147 and conferring protection against infection and/or disease caused by multiple Plasmodial strains or Plasmodial species, inhibitors of the interaction between Rh5 and CD147 and methods for producing polypeptides in a mammalian expression system.Type: ApplicationFiled: October 7, 2011Publication date: April 3, 2014Applicant: Genome Research LimitedInventors: Gavin J. Wright, Julian C. Rayner, Cecile Crosner, Leyla Y. Bustamante, S. Josefin Bartholdson
-
Publication number: 20140050711Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.Type: ApplicationFiled: March 14, 2013Publication date: February 20, 2014Inventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
-
Patent number: 8617820Abstract: An immunoassay reagent is provided which comprises an analyte binding agent in a diluent, and a glycosaminoglycan in an amount sufficient to reduce non-specific binding in an assay of a sample for the analyte. Provided is such an immunoassay reagent in which the analyte is troponin I, the analyte binding agent is a biotinylated anti-troponin I antibody, and the glycosaminoglycan is chondroitin sulfate. A sample composition is also provided which comprises a sample to be assayed for the presence of an analyte, an analyte binding agent, and a glycosaminoglycan other than heparin. Further provided is a method of detecting an analyte in a sample, in which non-specific binding is reduced in the method using a glycosaminoglycan.Type: GrantFiled: August 28, 2007Date of Patent: December 31, 2013Assignee: Ortho-Clinical Diagnostics, Inc.Inventors: Banumathi Sankaran, Sheryl S. Sullivan, Darrell C. Haynes, Philip C. Hosimer, Graham Yearwood
-
Patent number: 8617805Abstract: The present invention relates to novel methods for detecting at least one member of a known binding pair in a sample, including a cell, where one member of the pair (termed the “receptor”) is expressed by a bacteriophage, which phage is then used to detect the presence of the other member of the pair (termed the “ligand” or “target”). Rather than detecting the binding of at least one phage using antibody-based technology, the present invention relates to detecting the nucleic acid associated with the phages. In one aspect, the invention relates to identifying at least one antigen-bearing moiety (e.g., a red blood cell antigen) of interest present on a cell, e.g., a red blood cell, using antibody-displaying bacteriophages, using antiglobulin reagent-displaying bacteriophages and detecting at least one nucleic acid associated with the phage.Type: GrantFiled: October 22, 2004Date of Patent: December 31, 2013Assignee: The Trustees of the University of PennsylvaniaInventor: Donald L. Siegel
-
Patent number: 8614066Abstract: Lysing agents that are free of ligands, including cyanide, for binding hemoglobin for hematology analyzers. The ligand-free lysing agents achieve accurate quantification of hemoglobin parameters, thereby replacing existing lysing agents for analysis of hemoglobin.Type: GrantFiled: August 13, 2010Date of Patent: December 24, 2013Assignee: Abbott LaboratoriesInventor: Jiong Wu
-
Publication number: 20130337475Abstract: Expedient and sensitive detection of a detection target substance is enabled in target substance detection that detects the detection target substance at a sensor portion provided within a flow channel. A detection target substance detecting method for a detecting detection target substance which may be contained in a liquid sample emits ultrasonic waves that propagate in a direction transverse to a flow channel when the liquid sample flows within a ultrasonic wave emission region at which ultrasonic waves can be emitted, to concentrate the detection target substance at a wall surface of the flow channel toward the side of the sensor portion and to detect the detection target substance.Type: ApplicationFiled: August 20, 2013Publication date: December 19, 2013Applicant: Fujifilm CorporationInventor: Kazuyoshi HORII
-
Patent number: 8603828Abstract: Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided.Type: GrantFiled: November 8, 2010Date of Patent: December 10, 2013Assignee: Bio-Rad Laboratories, Inc.Inventors: Roger Walker, Benedicte Jardin
-
Publication number: 20130323757Abstract: The method according to the invention is capable of characterizing a variation in the speed of particles or agglomeration of particles, the particles, such as blood particles, being contained in a liquid (12). The characterization method includes the following steps: introducing the liquid (12) into a fluid chamber (14); lighting the fluid chamber (14) using an excitation laser beam (18) emitted by a light source (16), the laser beam (18) extending through the fluid chamber (14) in a longitudinal direction (X); acquiring at least one image using a matrix photodetector (20), the image being formed by radiation transmitted by the lighted fluid chamber (14); and calculating, from at least one acquired image, at least one indicator characterizing the variation of the speed or agglomeration of the particles. During the acquisition step, the photodetector (20) is positioned at a distance (D2) smaller than 1 cm from the fluid chamber (14) in the longitudinal direction (X).Type: ApplicationFiled: May 30, 2013Publication date: December 5, 2013Inventors: Vincent POHER, Myriam-Laure Cubizolles, Patrick Pouteau, Cédric Allier, Johanna Spiaczka
-
Publication number: 20130310544Abstract: An objective is to provide screening methods for substances having an activity of promoting maturation into hemocytes. It was revealed that in the maturation process of erythrocytes and platelets, RP S19 multimers are released to the outside of the cell and act on the C5a receptors of erythroblasts and megakaryocytes, thereby causing maturation of erythroblasts and megakaryocytes to erythrocytes and platelets. Based on such findings, the present invention provides methods of screening for substances having an activity of promoting maturation into hemocytes by targeting the RP S19 multimers and C5a receptors. The screening methods of the present invention can detect hemocyte maturation using an increase of the R4 RGS family as an indicator. Furthermore, the present invention provides agents for promoting hemocyte maturation, which comprise RP S19 multimers and a substance having an activity of promoting maturation into hemocytes as useful components.Type: ApplicationFiled: May 13, 2011Publication date: November 21, 2013Applicants: Chugai Seiyaku Kabushiki Kaisha, National University Corporation Kumamoto UniversityInventors: Tetsuro Yamamoto, Hiroshi Nishiura, Hideki Saito
-
Patent number: 8586321Abstract: A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains DNA (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample.Type: GrantFiled: November 4, 2011Date of Patent: November 19, 2013Assignee: Litron Laboratories, Ltd.Inventor: Stephen D. Dertinger
-
Patent number: 8586293Abstract: The present invention relates to novel methods for detecting a member of a known binding pair in a sample, including a cell, where one member of the pair (termed the “receptor”) is expressed by a bacteriophage, which phage is then used to detect the presence of the other member of the pair (termed the “ligand” or “target”). Rather than detecting the binding of the phage using antibody-based technology, the present invention relates to detecting the nucleic acid associated with the phage. In one aspect, the invention relates to identifying an antigen-bearing moiety (e.g., a red blood cell antigen) of interest present on a cell, e.g., a red blood cell, using antibody-displaying bacteriophage, as well as detecting anti-red blood cell auto- or alloantibodies and/or complement in a sample, using antiglobulin reagent-displaying bacteriophage and detecting a nucleic acid associated with the phage.Type: GrantFiled: March 8, 2005Date of Patent: November 19, 2013Assignee: The Trustees of the University of PennsylvaniaInventor: Donald L. Siegel
-
Patent number: 8586291Abstract: The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.Type: GrantFiled: March 11, 2009Date of Patent: November 19, 2013Assignee: The Regents of the University of CaliforniaInventors: Charles L. Sawyers, Mercedes E. Gorre, Neil Pravin Shah, John Nicoll
-
Patent number: 8580531Abstract: The invention relates to a method for detecting a plurality of antigenic molecules carried by erythrocytes and/or a plurality of anti-erythrocyte antibodies, said antigenic molecules carried by the erythrocytes consisting of antigenic molecules carried not only by the erythrocytes, but also by at least one other cell population, other than the blood group antigen molecules, said method comprising bringing a sample into contact with distinguishable beads, on which are attached a) antibodies specific for said antigens, or b) erythrocytes or erythrocyte membrane fragment.Type: GrantFiled: June 6, 2008Date of Patent: November 12, 2013Assignee: Bio-Rad InnovationsInventors: Frederic Buffiere, Yves Raisin, Eliane Rivalin, Amparo Sanjuan
-
Patent number: 8580530Abstract: The invention relates to a method for detecting a plurality of antigenic molecules carried by erythrocytes and/or a plurality of anti-erythrocyte antibodies of an individual, comprising bringing a sample into contact with distinguishable beads, on which are attached a) antibodies specific for said antigens, or b) erythrocytes, erythrocyte membrane fragments or blood group antigens.Type: GrantFiled: June 6, 2008Date of Patent: November 12, 2013Assignee: Bio-Rad InnovationsInventors: Frederic Buffiere, Yves Raisin, Eliane Rivalin, Amparo Sanjuan
-
Patent number: 8574913Abstract: Hemoglobin in a sample solution is quickly and reliably denatured; at the same time, quick and accurate measurement of hemoglobin and a hemoglobin derivative is realized. In a method for measuring hemoglobin and a hemoglobin derivative, and a reagent composition, a measurement kit, an analysis device, and an analysis system used in the method, a sample solution containing a blood component is treated with a nonionic surfactant, an oxidizing agent, and a metal salt to denature hemoglobin in the sample solution to measure the hemoglobin, and thereafter the amount of a hemoglobin derivative in the sample is measured by an immunological method using an antibody specifically binding to a denatured site of the denatured hemoglobin derivative.Type: GrantFiled: October 29, 2008Date of Patent: November 5, 2013Assignee: Panasonic CorporationInventors: Hirotaka Tanaka, Masanori Tanaka
-
Patent number: 8568994Abstract: The invention discloses a method of prenatal diagnosis comprising the step of isolating exosomes from an isolated fluid, wherein the exosomes are identified by biomarker detection. Furthermore, the invention discloses the isolation of exosomes from an isolated fluid and the use of a biomarker, particularly CD24 to isolate exosomes from an isolated fluid.Type: GrantFiled: August 1, 2008Date of Patent: October 29, 2013Assignee: DKFZ Deutsches Krebsforschungszentrum, Stiftung des Offentlichen RechtsInventors: Peter Altevogt, Sascha Keller
-
Patent number: 8563330Abstract: The invention provides a device and method for the rapid identification of patients suspected of having thalassemia. The invention provides a test strip for the aqueous detection of thalassemia related proteins in whole blood. The test strip includes antibodies specific to the gamma 4, (?4) protein and provides easy visual discrimination between a positive result and a negative result. The invention can be used in remote or clinical settings.Type: GrantFiled: March 21, 2008Date of Patent: October 22, 2013Assignee: National Science and Technology Development AgencyInventors: Watchara Kasinrerk, Chatchai Tayapiwatana, Thanusak Tatu, Suthat Fucharoen, Sawitree Chiampanichayakul
-
Patent number: 8563259Abstract: A method for assessing the presence of an acquired thrombophilia disorder in a patient exhibiting hypercoagulation is disclosed.Type: GrantFiled: June 25, 2008Date of Patent: October 22, 2013Assignee: The Trustees of the University of PennsylvaniaInventors: John D. Lambris, Konstantinos Ritis
-
Publication number: 20130273571Abstract: The present invention relates to producing more densely functionalized indicator cells which along, with other components, can be used to detect the presence or absence of antibodies or antigens, by using the A, B, AB and MNS antigens which have a greater degree of expression than the conventionally used D antigen to label the indicator cells with IgG. The present antigen systems have levels of expression that approach one million antigens per cell, which is in great contrast to the conventional D antigen sites of about 10,000-30,000 antigens per cell. This marked increase in the antigen systems level of expression could produce a boost in the kinetics and the magnitude of the binding of the indicator cell to the solid phase, which improves assay performance.Type: ApplicationFiled: May 5, 2011Publication date: October 17, 2013Applicant: ARRYX, INC.Inventors: Christopher Knutson, Derek David Doorneweerd
-
Patent number: 8557590Abstract: A method for measuring glycated hemoglobin includes hemolyzing a blood sample with a hemolysate; reacting the hemolyzed blood sample with bead conjugates in which beads are conjugated with glycated hemoglobin binding materials; measuring the amount of total hemoglobin in the reacted blood sample; isolating normal hemoglobin from the glycated hemoglobin conjugated with the bead conjugates; measuring the amount of glycated hemoglobin isolated from the normal hemoglobin; and determining the percentage of the glycated hemoglobin in the blood sample on the basis of the measured amounts of total hemoglobin and glycated hemoglobin. The isolation of normal hemoglobin is performed by absorbing the normal hemoglobin using an absorption pad that is a porous pad having pores, each of which has a size greater than the size of the normal hemoglobin and smaller than the size of the bead.Type: GrantFiled: December 19, 2011Date of Patent: October 15, 2013Assignee: Infopia Co., Ltd.Inventors: Byeong-Woo Bae, Sung-Dong Lee, Hyong-Soo Kim
-
ANTIBODY-LINKED IMMUNO-SEDIMENTATION AGENT AND METHOD OF ISOLATING A TARGET FROM A SAMPLE USING SAME
Publication number: 20130266930Abstract: The present disclosure is directed to antibody-linked immuno-sedimentation agent, the antibody being linked to a sedimentation agent by a non-antigen binding region of the antibody, and a method of isolating a target from a sample using the antibody-linked immuno-sedimentation agent. The methods involve forming a mixture including a sample with an antibody linked immuno-sedimentation agent and red blood cells under conditions sufficient to form red blood cell rouleaux and allow antibody-antigen binding.Type: ApplicationFiled: March 13, 2013Publication date: October 10, 2013Applicant: CytoSed, Inc.Inventor: Warren L. Dinges -
Publication number: 20130260396Abstract: The present invention relates to an instrument and a measurement apparatus and methodology that yields a measurement and test methodology that characterizes a population of cells/particles or detects a sub-population of cells/particles based on their detected mobility in a quick and efficient manner.Type: ApplicationFiled: May 25, 2011Publication date: October 3, 2013Applicant: ARRYX, INC.Inventor: Osman Akcakir
-
Patent number: 8536312Abstract: The present invention concerns a monoclonal antibody and corresponding hybridoma cells and antigens suitable for isolating fetal cells from maternal blood. The inventive monoclonal antibody reacts with a surface antigen present on fetal red blood cells including their nucleated precursor cells, but not with surface antigens on adult erythroid cell.Type: GrantFiled: December 28, 2010Date of Patent: September 17, 2013Assignee: Adnagen GmbHInventors: Christiane Hollmann, Silke Zimmermann, Stefan Stachelhaus, Winfried Albert
-
Publication number: 20130209988Abstract: Methods and systems for selectively capturing analytes, such as cells, e.g., circulating tumor cells (CTCs), from fluid samples are disclosed. The methods include contacting the sample with an analyte binding moiety that selectively binds to the analytes; optionally separating first components of the sample including a majority of the analytes bound to the binding moieties from second components of the sample using size-based separation, e.g.Type: ApplicationFiled: November 23, 2010Publication date: August 15, 2013Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Thomas A. Barber, Ajay Shah, John Walsh, Mehmet Toner, Ravi Kapur, Shannon L. Stott
-
Patent number: 8507237Abstract: The invention concerns a device and a method for concentrating pathogenic germs potentiaily present in blood products or derivatives and for detecting said germs comprising the following steps: (a) subjecting a sample of said blood product to a blood cell aggregating treatment, (b) eliminating the aggregates formed at step (a) by passing the treated sample over a first filter allowing through the contaminating germs but not the cell aggregates, (c) selectively lyzing the residual cells of the filtrate obtained at step (b), (d) recuperating the contaminating germs by passing the lysate of step (c) over a second filter to detect the contaminating germs possibly trapped.Type: GrantFiled: March 8, 2004Date of Patent: August 13, 2013Assignee: GeneOhm Sciences, Inc.Inventors: Jean-Pierre Hermet, Isabelle Besson-Faure, Sébastien Ribault, Yann Godfrin, Anne Monnot des Angles
-
Publication number: 20130164763Abstract: An analysis device includes: a separation cavity 18 for separating a test liquid into a solution component and a solid component by using a centrifugal force; a higher specific gravity component quantitative cavity 23 for holding a portion of the separated solid component which has been transferred; a sample solution overflow cavity 22 arranged between the higher specific gravity component quantitative cavity 23 and the separation cavity 18 and connected to a connecting channel 21 for transporting the sample liquid from the separation cavity 18; and a capillary cavity 19 formed in the separation cavity 18 for temporarily holding a separated solution component (blood plasma) in the separation cavity 18. A blood plasma component 57a remaining in the separation cavity 18 is trapped by the capillary cavity 19.Type: ApplicationFiled: February 19, 2013Publication date: June 27, 2013Applicant: PANASONIC CORPORATIONInventor: PANASONIC CORPORATION
-
Publication number: 20130164736Abstract: The present invention relates to a method for detecting molecular interactions in a solution. In particular, the present invention relates to a method for detecting interactions between two substances that are likely to interact with one another. The present invention can be used in particular in the field of scientific research and in the field of medical analysis.Type: ApplicationFiled: June 30, 2011Publication date: June 27, 2013Applicant: BIOFILM CONTROLInventors: Thierry Bernardi, Pascal Mayer, Jérôme Groelly
-
Publication number: 20130156786Abstract: The present invention relates to a peptide or peptide complex binding to ?2 integrin, to one or more nucleic acid(s) coding for the peptide or peptide complex, a recombinant cell producing the peptide or peptide complex, a method for producing the peptide or peptide complex, a pharmaceutical composition comprising the peptide or peptide complex or the nucleic acid(s) for use as a medicament, a method for detecting ?2 integrin and a screening method.Type: ApplicationFiled: August 30, 2011Publication date: June 20, 2013Applicant: SANOFIInventors: Carsten Corvey, Horst Blum, Béatrice Cameron, Tarik Dabdoubi, Stephanie Decary, Nicolas Baurin, David Papin, Christian Lange
-
Patent number: 8465988Abstract: Methods are provided herein for determining antioxidant activity of a test sample in intact cells. The method includes determining the antioxidant capacity of a test sample in intact red blood cells, wherein the test sample is added to intact red blood cells and oxidative damage is measured by alteration of fluorescence intensity of an oxidation-sensitive fluorescent indicator dye.Type: GrantFiled: October 31, 2008Date of Patent: June 18, 2013Assignee: Natural Immune Systems, Inc.Inventor: Gitte S. Jensen
-
Publication number: 20130130280Abstract: The current invention relates to a magnetic immunodiagnostic method for the demonstration of antibody/antigen complexes of blood group and phenotype. Such a method involves the research and/or identification of antibodies or antigens, preferably anti-antigen antibodies or antigens of a blood group. This method implements a suspension of magnetic particles coated with an antibody anti-glycophorin A that can recognize and specifically magnetize erythrocytes. The invention also includes a device and kit for carrying out one such method.Type: ApplicationFiled: July 21, 2011Publication date: May 23, 2013Applicant: DIAGASTInventors: Laurence Fauconnier, Yves Barbreau, Arnaud Boulet, Maha Zakhour
-
Patent number: 8426210Abstract: Disclosed herein are antibodies, systems and methods for assessing the risk of hemolysis following a blood transfusion with crossmatch incompatible blood. The disclosure provides a method for determining the relative hemolytic index and therefore the risk of post-transfusion hemolysis for said patient.Type: GrantFiled: October 20, 2010Date of Patent: April 23, 2013Assignee: New York Blood Center, Inc.Inventor: Gregory R. Halverson
-
Publication number: 20130078259Abstract: A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of three recombinant pneumococcal neuraminidases: NanA, NanB, and NanC of S. pneumoniae strains CGSP14, wherein administration of the recombinant pneumococcal neuraminidases elicits an immune response to S. pneumoniae, and treats the subject. In one embodiment, the method further includes a step of adding adjuvants to enhance the immune response. The method also includes a step of using passive antibodies, wherein said passive antibodies are anti-neuraminidase antibodies generated from neuraminidases-immunized humanized animals: NanA, NanB, and NanC. Meanwhile, this invention also provides a method for the molecular diagnosis of pneumococcal infection.Type: ApplicationFiled: September 25, 2011Publication date: March 28, 2013Applicant: CHANG GUNG MEDICAL FOUNDATION, LINKOU BRANCHInventors: Cheng-Hsun Chiu, Rajendra Prasad Janapatla, Chyi-Liang Chen, Mei-Hua Hsu, Hsiu-Ling Chen, Chung-Tsui Huang, Hsin-Ju Chang, Wan-Ting Liao
-
Publication number: 20130078620Abstract: The present invention provides a method and device for detecting and quantifying the concentration of magnetic-responsive micro-beads dispersed in a liquid sample. Also provided is a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a sample medium by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD4+, CD8+ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.Type: ApplicationFiled: November 26, 2012Publication date: March 28, 2013Inventors: Alberto Gandini, James F. Antaki
-
Patent number: 8404456Abstract: The present invention provides compositions and methods for treating or preventing antibody mediated graft rejection and blood typing.Type: GrantFiled: February 28, 2011Date of Patent: March 26, 2013Assignee: AbSorber ABInventors: Jan Holgersson, Jining Liu, Linda Lindberg, Per Grufman
-
Publication number: 20130064940Abstract: The disclosure is related generally to methods for testing mammary fluid (including milk) to establish or confirm the identity of the donor of the mammary fluid. Such methods are useful in the milk-bank business to improve safety.Type: ApplicationFiled: August 23, 2012Publication date: March 14, 2013Applicant: Prolacta Bioscience, Inc.Inventors: Elena M. MEDO, Martin L. Lee, David J. Rechtman
-
Patent number: 8394594Abstract: Peptide-lipid constructs of the structure L-S-F are disclosed, where F is a peptide, S is a spacer covalently linking F to L via an oligomer of ethylene glycol, and L is a diacyl- or dialkyl-glycerolipid (including glycerophospholipids). The spacer ideally has 6 to 14 ethylene glycol repeats, corresponding to PEG with a molecular weight of approximately 250 to 600. Also disclosed is a method of detecting reactive antibodies in serum by contacting serum with cells modified to incorporate a peptide-lipid construct, where the peptide is an epitope of the antibody, and determining the degree of aggluthination of the cells.Type: GrantFiled: September 11, 2008Date of Patent: March 12, 2013Assignee: Kode Biotech LimitedInventors: Cristina-Simona Weinberg, Nicolai Bovin, Stephen Micheal Henry
-
Patent number: 8383410Abstract: The invention concerns an internal standard used to quantitative analysis of the risk of humoral (i.e. vascular) transplant rejection. The internal standard consists of a stable composition of the C4d complement bound to a carrier consisting of erythrocytes or microparticles. The invention also concerns a method for analyzing in vitro the risk of humoral organ transplant rejection, which consists in determining the amount of component of C4d component fixed on the erythrocytes contained in a blood sample from a patient.Type: GrantFiled: March 30, 2007Date of Patent: February 26, 2013Assignee: Universite de Reims Champagne-ArdenneInventors: Jacques Henri Max Cohen, Brigitte Reveil, Aymric Kisserli, Fadi Haidar, Béatrice Donvito
-
Patent number: 8383341Abstract: Method for non-invasive prenatal diagnosis comprising the following steps: a. obtain a sample of an organic fluid having a high probability of containing foetal cells from a pregnant woman; b. enrich said sample of organic fluid in at least one population of cells comprising at least one type of foetal nucleated cells; c. isolate at least one cell from among said at least one type of foetal nucleated cells; d. perform a genetic analysis on said at least one cell isolated from among said at least one type of foetal nucleated cells in order to highlight at least one genetic characteristic of said at least one foetal nucleated cell suitable for permitting said diagnosis; wherein the step of isolating at least one cell from among said at least one type of foetal nucleated cells is performed by individually selecting single cells in a microfluidic device designed for said purpose.Type: GrantFiled: May 2, 2008Date of Patent: February 26, 2013Assignee: Silicon Biosystems S.p.A.Inventors: Nicolò Manaresi, Antonio Fittipaldi, Giuseppe Giorgini, Gianni Medoro
-
Publication number: 20130040850Abstract: The invention provides methods and kits for measuring the ability of a test sample to inhibit the binding of a receptor expressed by a pathogen to a host cell ligand of the pathogen.Type: ApplicationFiled: April 18, 2011Publication date: February 14, 2013Applicant: MESO SCALE TECHNOLOGIES, LLC.Inventor: George Sigal
-
Patent number: RE43979Abstract: The invention relates to a method for detecting specific target-cells in a simple and time saving way, using paramagnetic particles, antibodies recognizing the Fc portions of target-cell associating antibodies and target-cell associating antibodies directed to specific antigen determinants in the target-cell membranes. Incubation of the cell suspension with a mild detergent and/or second set of antibodies or antibody fragments, prelabeled or not with fluorescent agents, metallocolloids, radioisotopes, biotincomplexes or certain enzymes allowing visualization, with dramatically increase the specificity of the method. The method can further be used for isolation of the target-cells by magnetic field application and kit for performing the method according to the invention is described.Type: GrantFiled: February 5, 2003Date of Patent: February 5, 2013Assignee: Abbott LaboratoriesInventors: Oystein Fodstad, Gunnar Kvalheim